Vessi Medical has secured $1.7 million in funding to advance its innovative cryoablation solution for superficial bladder cancer, positioned as a promising alternative to invasive surgical procedures.

Target Company Information

Vessi Medical, a company within The Trendlines Group portfolio, has successfully secured $1.7 million in funding aimed at advancing its innovative cryoablation solution for superficial bladder cancer. This funding round included participation from notable investors such as Agriline, The Trendlines Group, the Israel Innovation Authority, and ExitValley investors. Vessi Medical is planning a first-in-human (FIH) study to demonstrate the safety and efficacy of its intravesical cryotherapy device, with the study set to commence in the first quarter of 2021.

Vessi Medical addresses a significant medical need for the approximately two million individuals worldwide diagnosed with non-muscle invasive bladder cancer (NMIBC). Traditional treatments for NMIBC include invasive procedures that often result in complications and recurrent cancers, thereby diminishing patients' quality of life. The Vessi system aims to transform the treatment landscape by providing a less invasive, outpatient alternative.

Industry Overview in Israel

The medical technology industry in Israel is renowned for its innovation and entrepreneurial spirit, positioning the country as a leading hub for groundbreaking medical advancements. Home to numerous start